EXPERIMENTAL & CLINICAL MEDICINE GEORGIA,
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 21, 2024
The
human
microbiome,
comprising
trillions
of
bacteria,
fungi,
and
viruses,
profoundly
influences
both
our
organism
the
surrounding
environment.
Emerging
research
highlights
symbiotic
relationship
between
microbial
organisms,
suggesting
their
co-evolution
into
superorganisms.
Throughout
life,
gut
microbiome
undergoes
significant
shifts,
impacting
immune,
nervous,
cardiovascular
system
homeostasis.
Understanding
these
dynamics
offers
insights
personalized
medicine
therapeutic
interventions
targeting
dysbiosis.
Antibiotics,
Год журнала:
2025,
Номер
14(4), С. 371 - 371
Опубликована: Апрель 3, 2025
The
human
gut
microbiota—an
intricate
and
dynamic
ecosystem—plays
a
pivotal
role
in
metabolic
regulation,
immune
modulation,
the
maintenance
of
intestinal
barrier
integrity.
Although
antibiotic
therapy
is
indispensable
for
managing
bacterial
infections,
it
profoundly
disrupts
microbial
communities.
Such
dysbiosis
typified
by
diminished
diversity
shifts
community
structure,
especially
among
beneficial
genera
(e.g.,
Bifidobacterium
Eubacterium),
fosters
antibiotic-resistant
strains
horizontal
transfer
resistance
genes.
These
alterations
compromise
colonization
resistance,
increase
permeability,
amplify
susceptibility
to
opportunistic
pathogens
like
Clostridioides
difficile.
Beyond
gastrointestinal
disorders,
emerging
evidence
associates
with
systemic
conditions,
including
chronic
inflammation,
syndrome,
neurodegenerative
diseases,
underscoring
relevance
microbiota–gut–brain
axis.
recovery
pre-existing
communities
post-antibiotic
highly
variable,
influenced
drug
spectrum,
dosage,
treatment
duration.
Innovative
interventions—such
as
fecal
microbiota
transplantation
(FMT),
probiotics,
synbiotics,
precision
microbiome
therapeutics—have
shown
promise
counteracting
mitigating
its
adverse
effects.
therapies
align
closely
stewardship
programs
aimed
at
minimizing
unnecessary
use
preserve
curtail
spread
multidrug-resistant
organisms.
This
review
emphasizes
pressing
need
microbiota-centered
strategies
optimize
administration,
promote
long-term
health
resilience,
alleviate
disease
burden
associated
antibiotic-induced
dysbiosis.
Health Science Reports,
Год журнала:
2023,
Номер
6(7)
Опубликована: Июль 1, 2023
Abstract
Background
and
Aims
SARS‐CoV‐2,
as
a
new
pandemic
disease,
affected
the
world.
Short‐chain
fatty
acids
(SCFAs)
such
acetic,
propionic,
butyric
are
main
metabolites
of
human
gut
microbiota.
The
positive
effects
SCFAs
have
been
shown
in
infections
caused
by
respiratory
syncytial
virus,
adenovirus,
influenza,
rhinovirus.
Therefore,
this
study
aimed
to
evaluate
concentration
patients
with
SARS‐CoV‐2
compared
healthy
group.
Methods
This
research
was
designed
based
on
case
control
study.
Twenty
individuals
group
20
persons
admitted
hospital
test
coronavirus
disease
(COVID‐19)
real‐time
polymerase
chain
reaction
were
included
patient
from
September
2021
October
2021,
Tabriz,
Iran.
Stool
specimens
collected
volunteers,
analysis
carried
out
high‐performance
liquid
chromatography
system.
Results
amount
acetic
acid
67.88
±
23.09
μmol/g,
while
COVID‐19
37.04
13.29
μmol/g.
significantly
(
p
<
0.001)
lower
than
Propionic
present
higher
group;
however,
value
not
statistically
significant
>
0.05).
Conclusion
showed
that
metabolite
microbiota
is
disturbed
COVID‐19.
therapeutic
interventions
future
may
be
effective
against
Parasites Hosts and Diseases,
Год журнала:
2024,
Номер
62(4), С. 408 - 423
Опубликована: Ноя. 22, 2024
Toxoplasma
gondii
primarily
invades
the
central
nervous
system,
causing
latent
infections.
Cysts
persist
in
host
for
life
and
there
is
currently
no
effective
treatment.
T.
infects
human
hosts
through
contaminated
meat,
invading
intestinal
tissue
leading
to
changes
number
composition
of
gut
microbiota.
Since
probiotic
ingestion
modulates
microbiota
changes,
we
hypothesized
that
dysbiosis
caused
by
infection
would
be
restored
following
supplementation.
To
this
end,
orally
infected
C57BL/6
mice
with
10
cysts
administered
supplemental
probiotics
daily.
We
analyzed
levels
B1
gene
DNA,
indicative
infection,
brain
tissue.
investigated
alterations
functional
pathways
between
non-probiotic
treatment
groups
via
next-generation
sequencing
analysis
each
fecal
sample.
The
level
probiotic-treated
group
was
significantly
reduced
after
4
weeks
(p<0.05).
Probiotic
supplementation
notably
changed
2
increasing
relative
abundance
Intestinimonas
massiliensis
Lawsonibacter
asaccharolyticus.
supplements
appear
modulate
microbiota,
activating
involved
short-chain
fatty
acid
production
strengthening
barrier,
thereby
impeding
subsequent
proliferation.
Our
findings
provide
valuable
insights
into
control
future
study
directions.
